Description: CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Home Page: www.cero.bio
201 Haskins Way
South San Francisco,
CA
94080
United States
Phone:
215 731 9450
Officers
| Name | Title |
|---|---|
| Mr. Christopher B. Ehrlich M.B.A. | CEO & Chair |
| Mr. Brian G. Atwood | President & Director |
| Dr. Lawrence Corey M.D. | Co-founder & Head of Scientific Advisory Board |
| Mr. Andrew Albert Kucharchuk M.B.A. | CFO & Director |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer & Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-02-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |